发布时间：2026-02-02 14:15 First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform
SHANGHAI--(BUSINESS WIRE)--Tenacia Biopharmaceuticals (Shanghai) Co., Ltd.("Tenacia") andGOLDEN AGE HEALTH (SHANGHAI) CO., LTD.,a subsidiary of Golden Age Health Pte. Ltd. (collectively, "GAH") today announced aCommercialization Agreementgranting GAH exclusive rights to commercializeZTALMY®(泽元安), the first and as of now only approved treatment forCDKL5 deficiency disorder (CDD)in Mainland China.

ZTALMY®(ganaxolone oral suspension) was developed by Marinus and Tenacia obtains exclusive rights to develop and commercialize it in Greater China. In July 2024, the drug was approved by the National Medical Products Administration for treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.

Tenacia has partnered with GAH to leve
=*=*=*=*=*=
当前为第1/5页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页